Inactive Instrument

Abcam plc London S.E.

ABC

GB00B6774699

Abcam plc Provides Trading Guidance for the Six Months Ended December 31, 2016 and Fiscal Year 2017

January 10, 2017 at 12:30 pm IST

Abcam plc provided trading guidance for the six months and year ended December 31, 2016. Overall the company expects revenue growth of 10.0% on a constant currency basis and 30.4% on a reported basis. The company remains on track to deliver against revenue expectations for the full year.

Latest news about Abcam plc

Global markets live: Mastercard, Diageo, Nvidia, Airbnb, Exxon Mobil...	06/12
Job losses delight investors	06/12
Danaher Closes Acquisition of Abcam	06/12	MT
Danaher completes $5.7 billion acquisition of Abcam	06/12	RE
Abcam plc(NasdaqGS:ABCM) dropped from NASDAQ Composite Index	06/12	CI
Abcam plc(NasdaqGS:ABCM) dropped from NASDAQ Biotechnology Index	06/12	CI
Abcam plc(NasdaqGS:ABCM) dropped from S&P Global BMI Index	06/12	CI
Danaher Corporation completed the acquisition of Abcam plc.	06/12	CI
Abcam's Acquisition by Danaher Approved by UK Court	05/12	MT
Abcam Says All Necessary Clearances for Acquisition by Danaher Obtained; Deal Set to be Completed on Dec. 6	17/11	MT
All good things must come to an end	07/11
Abcam Shareholders Approve Danaher's Acquisition Offer	07/11	MT
Abcam shareholders approve $5.7 billion Danaher deal	07/11	RE
Jonathan Milner Suspends his Vote Against Campaign	01/11	CI
RBC Trims Price Target on Abcam to $24 From $25, Keeps Sector Perform Rating	31/23/31	MT
Jonathan Milner Issues Statement Responding to the Glass Lewis Report	23/23/23	CI
Jonathan Milner Continues Opposition to Danaher Corporation Acquisition	18/23/18	CI
Institutional Shareholder Services Recommends Shareholders Vote for Danaher Corporation?s Proposed Acquisition of Abcam plc	17/23/17	CI
Jonathan Milner Releases Presentation to Abcam plc Shareholders	16/23/16	CI
Jonathan Milner issues Open Letter to shareholders of Abcam plc	10/23/10	CI
Abcam Sends Letter Seeking Shareholders' Approval of Danaher's Takeover Offer	05/23/05	MT
Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher	05/23/05	CI
Jonathan Milner issues Open Letter to Shareholders of Abcam plc	28/23/28	CI
Abcam founder says he will vote against $5.7 billion Danaher deal	14/23/14	RE
Abcam founder Jonathan Milner opposes Danaher deal	14/23/14	RE

Chart Abcam plc

Duration

Period

More charts

Company Profile

Abcam plc is a global life science company. The Company serves customers at the forefront of life science research through the identification, development, and distribution of biological reagents. Its products are used by researchers around the world to study biological pathways critical for scientific research, diagnostics, and drug discovery. It offers a selection of products in its catalogue to support research on proteins in biological pathways. Its principal catalogue product lines include primary and secondary antibodies, conjugated antibodies and conjugation kits, and singleplex immunoassays. It offers a range of peptides and proteins, which include cytokines, growth factors, and enzymes. It offers a range of knockout cell lines and lysates, which are used for its in-house validation needs and are also made available to its customers for their own research. It offers a variety of other products, including cellular activity kits, biochemicals and cell signaling pathway tools.

Sector

Pharmaceuticals

Calendar

09/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	+8.08%	10TCr
SAMSUNG BIOLOGICS CO.,LTD.	+11.97%	4.23TCr
BIOGEN INC.	-11.76%	3.28TCr
UCB	+79.34%	2.95TCr
BIOMARIN PHARMACEUTICAL INC.	-12.20%	1.63TCr
INCYTE CORPORATION	+4.00%	1.44TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-1.90%	1.22TCr
ALTEOGEN INC.	+178.17%	1.05TCr
SWEDISH ORPHAN BIOVITRUM AB	+1.80%	896.68Cr

Biopharmaceuticals